8th Conference on Retroviruses and Opportunistic Infections Chicago, IL - February 4 - 8, 2001

Conf Retroviruses Opportunistic Infect 2001 Feb 4-8; 8:47 (abstract no. 15)

K. Squires¹, J. Gatell², P. Piliero³, I. Sanne⁴, R. Wood⁵, and S. M. Schnittman^6
1Univ. of Alabama at Birmingham; ²Hosp. Clin. y Provincial, Barcelona, Spain; ³Albany Med. Coll., NY; ⁴WHC Infectious Diseases Clin. Trials Unit, Johannesburg, South Africa; ⁵Diana, Princess of Wales HIV Res. Fndn., Capetown, South Africa; and ⁶Bristol-Myers Squibb, Wallingford, CT.

BACKGROUND: BMS-232632 (BMS) is a PI with potent activity in vitro (EC₅₀2-5 nM), a favorable resistance profile, and a PK profile that supports once-daily dosing.

METHODS: This phase II, 2-staged randomized study compares the safety and antiretroviral activity of 3 dose levels of BMS with nelfinavir (NFV) 750 mg tid both as monotherapy (2 wk) and in combination with didanosine (ddI) and stavudine (d4T) in antiretroviral-naïve subjects with greater than or equal to 2000 copies/mL HIV RNA. Interim analyses at 24 and 48 wk were planned.

RESULTS: Ninety-two subjects were treated (98 randomized) in stage I (med f/u 32 wk), and 166 were treated (265 randomized) in stage II (med f/u 16 wk). Baseline RNAs were 4.80 and 4.65 log₁₀ copies/mL in the 2 stages, respectively. Significant proportions of subjects achieved <400 and <50 copies/mL HIV RNA in all treatment groups at 12 (stage II) and 24 wk (stage I). For example, with BMS 400 mg once daily at 12 wk in stage II (n=265), 70% of subjects achieved <400 copies/mL and 31% achieved <50 copies/mL HIV RNA. BMS has been well tolerated both alone and in combination. Common adverse events in stage II were diarrhea (17% BMS, 51% NFV), infection and nausea (13% BMS, 7% NFV). Asymptomatic unconjugated hyperbilirubinemia not associated with hepatic transaminitis, the most common lab abnormality seen with BMS (71%), was dose dependent and predominantly grade 1-2. Increases in CD4+ cell count were seen in all treatment groups. To date, no significant elevations in cholesterol, LDL-cholesterol, or triglycerides were observed in the BMS arm, in contrast to the NFV arm, which demonstrated prompt, sustained rises of 20-50 mg/dL. Results of stage I, 48 wk efficacy and safety including lipid measurements will be presented.

CONCLUSIONS: These results support the safety and tolerability and antiretroviral efficacy of BMS as a once-daily PI in a combination regimen compared with a reference regimen.

2001-02-04
15

Copyright © 2001 - Foundation for Retrovirology and Human Health. Reproduction of this abstract (other than one copy for personal reference) must be cleared through the Foundation for Retrovirology and Human Health. Licensed (AIDSLINE) from National Library of Medicine.